This article describes how behavioral science can be applied in cardiometabolic clinical research to augment drug interventions. This combined approach addresses the Health Inequity gap while also increasing patient engagement.
The Latest Resources for Clinical Developments and Insights
The Latest Resources for Clinical Developments and Insights
We’re ushering in a new generation of clinical discovery with resources to match. Catch up with the thought leaders at Clinical ink, learn more about our technology solutions, and stay up-to-date with the latest industry news. Access our library of resources, including blogs, events, whitepapers, and more.
Latest from the Newsroom
The recent FDA publication "Submitting Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials'' represents a significant leap forward in cancer research and drug development. This detailed guidance for integrating PROs into the drug approval process sets a new standard for the evaluation of cancer treatments.
Clinical ink is expanding its patient engagement suite with the inclusion of the SPUR™ behavioral diagnostic tool created by Observia.
Clinical ink is setting a new industry benchmark in advancing study build timelines. Harnessing the power of the latest eCOA technology, Clinical ink can now reduce study build timelines to as little as 10 days.
